Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN3014 (HexaBody-CD38) in relapsed or refractory multiple myeloma and other hematologic malignancies
2023-507086-26-00Phase 2Completed
- Sponsor
- Genmab
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 2, randomised, open-label trial of gen3014 in multiple myeloma (MM), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by Genmab. Primary endpoints: Incidence of dose-limiting toxicities, Safety and 1 more. Started Sep 2024; status: completed.
02
Drugs
gen3014
03
Conditions
multiple myeloma (MM)acute myeloid leukemia (AML)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2023-507086-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507086-26-00.